Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment

Krakow, Elizabeth F.; Bergeron, Julie; Lachance, Silvy; Roy, Denis‐Claude; Delisle, Jean-Sébastien

doi:10.1016/j.blre.2014.08.002

Cited by 15 publications

(10 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both NK cell alloreactivity and T cell alloreactivity generate anti-leukaemic effects; however, long-term disease control requires recipient-derived T cell responses against tumour-associated antigens. Several variables that may affect the NEACT effect are the release of proinflammatory cytokines such as IL-6 and the choice of different pretreatment chemotherapy [36]. Further analysis of cytokine release after NEACT and its correlation with disease progression and survival is required.…”

Section: Nk Cell-based Immunotherapy For Haematologic Malignanciesmentioning

confidence: 98%

“…We have reported altered cytokine profiles in AML patients including increased levels of IL-6 that inversely correlated with survival [68] and may affect NEACT effectiveness. In addition, donor selection, the characteristics of infused cells and the use of repeated infusions are questions to be addressed [36].…”

Section: Nk Cell-based Immunotherapy For Haematologic Malignanciesmentioning

confidence: 99%

See 1 more Smart Citation

Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?

Sánchez-Correa

Campos

Pera

et al. 2015

Cancer Immunol Immunother

View full text Add to dashboard Cite

Several age-associated changes in natural killer (NK) cell phenotype have been reported that contribute to the defective NK cell response observed in elderly patients. A remodelling of the NK cell compartment occurs in the elderly with a reduction in the output of immature CD56(bright) cells and an accumulation of highly differentiated CD56(dim) NK cells. Acute myeloid leukaemia (AML) is generally a disease of older adults. NK cells in AML patients show diminished expression of several activating receptors that contribute to impaired NK cell function and, in consequence, to AML blast escape from NK cell immunosurveillance. In AML patients, phenotypic changes in NK cells have been correlated with disease progression and survival. NK cell-based immunotherapy has emerged as a possibility for the treatment of AML patients. The understanding of age-associated alterations in NK cells is therefore necessary to define adequate therapeutic strategies in older AML patients.

show abstract

Section: Nk Cell-based Immunotherapy For Haematologic Malignanciesmentioning

confidence: 98%

Section: Nk Cell-based Immunotherapy For Haematologic Malignanciesmentioning

confidence: 99%

Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?

Sánchez-Correa

Campos

Pera

et al. 2015

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Indeed, many clinical trials have reported the power of alloreactivity to treat MRD, whereas overt disease is often resistant to cellular immunotherapy [23]. Moreover, at this stage, well-designed multicenter, randomized clinical studies (see below) should be planned to provide definitive proof of the efficacy of NK-based cellular therapy.…”

mentioning

confidence: 99%

Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia

Lemoli

Parisi

Curti

2017

Experimental Hematology

View full text Add to dashboard Cite

Although many attempts have been made to identify novel molecular-targeted therapies for patients with acute myeloid leukemia, their translation into the clinic have had limited impact. In particular, the question of effective and curative treatments for elderly patients, who are not eligible for stem cell transplantation, remains an unmet medical need. To answer this question, a wide range of immunologic therapeutic strategies, mostly T cell based, have been proposed and investigated. At present, however, the clinical results have been largely unsatisfactory. Natural killer cells have recently been used as a means of adoptive immunotherapy with promising clinical results. On the basis of recent clinical reports and moving from the basic immunobiology of natural killer cells, here we discuss some open issues in the clinical translation of natural killer-based adoptive immunotherapy for the management of elderly patients with acute myeloid leukemia.

show abstract

“…In the UK, NHS Blood and Transplant provides pooled granulocytes from 10 random donor buffy coats that contain fewer neutrophils (mean dose 10·0 × 10 9 per unit) but typically more lymphocytes compared with an apheresis product (mean: 6·72 × 10 9 per unit) (Joint UKBTS Professional Advisory Committee, 2015). The infusion of buffy coat granulocytes, therefore, potentially constitutes a form of non-engrafting allogeneic cellular therapy that may have far-reaching consequences, especially for patients with acute myeloid leukaemia (AML) (Krakow et al, 2014). The ability of mismatched donor leukocyte infusions to induce transient remissions of acute leukaemia has been known for many years (Schwarzenberg et al, 1967).…”

Section: Dear Sirmentioning

confidence: 99%

Granulocyte infusion: benefit beyond neutrophils?

Creasey

Jones

Collin

2016

Transfusion Medicine

View full text Add to dashboard Cite

Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment

Cited by 15 publications

References 150 publications

Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?

Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?

Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia

Granulocyte infusion: benefit beyond neutrophils?

Contact Info

Product

Resources

About